FIELD: biotechnology.
SUBSTANCE: group of inventions relates to novel compounds which specifically recognize and bind Ang-2. Disclosed is a human lipolocalum mutein associated with neutrophil gelatinase (hNGAL) capable of binding Ang-2. Amino acid sequence of mutein hNGAL contains at least sixteen mutated amino acid residues at sequence positions 28, 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132 and 134 as compared to the mature polypeptide sequence of the mature hNGAL SEQ ID NO: 16 and has at least 85 % identity with respect to a sequence selected from SEQ ID NO: 1–14. Also disclosed are a method of producing hNGAL, a fusion protein, a composition and a combination containing hNGAL, a nucleic acid molecule encoding hNGAL, and a host cell for hNGAL gene expression.
EFFECT: mutein hNGAL can be used in various applications, including pharmaceutical applications for angiogenesis inhibition or reduction.
55 cl, 5 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
